METHYCLOTHIAZIDE Synthesis, SAR, MCQ,Structure,Chemical Properties and Therapeutic Uses

METHYCLOTHIAZIDE Synthesis, SAR, MCQ,Structure,Chemical Properties and Therapeutic Uses

Methyclothiazide

 

IUPAC nomenclature

6-Chloro-3-(chloromethyl)-2-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide

 

Classification

  • Thiazide diuretic

 

Physiochemical Properties

S. NO. PHYSICAL AND CHEMICAL PROPERTIES
1 Molecular weight 360.2 g/mol
2 Physical appearance White crystalline powder
3 Melting point 225oC
4 Solubility Slightly soluble in alcohol; freely soluble in acetone
5 Octanol/water partition coefficient 1.42
5 Presence of ring Benzothiazine
6 Number of chiral centers Not present

­­­­­

 

Mechanism of Action

  • Methyclothiazide prevents active chloride reabsorption at the early distal tubule through the sodium chloride contransportor which results in an increase in the excretion of sodium, chloride and water from the body.
  • The drug also binds with thiazide-sensitive Na-Cl transportor and prevents sodium ion transport across the renal tubular epithelium. This increases the potassium excretion through Na-K exchange mechanism.
  • It can also mediate its actions on carbonic anhydrase in the smooth muscle or on the large-conductance KCa channel found in smooth muscle.

 

Structure Activity Relationship

General structure activity of thiazide diuretics can be summarized as:

  • Chlorothiazide is the simplest member of the series.
  • Hydrogen atom at the 2-N is most acidic due to presence of electron-withdrawing group.
  • Sulfonamide group at C-7 position provides additional acidity to the drug.
  • Electron withdrawing group is essential at position 6 for diuretic activity of the drug.
  • Substitution oh hydrogen at 6 position gives little diuretic activity, whereas, substitution with chloro and trifluoromethyl groups gives highly active compounds.
  • Substitution of electron donating group at position 6 significantly reduces the diuretic activity.
  • Replacement or removal of sulfonamide groups from position 7 significantly reduces the diuretic activity.
  • Saturation of the double bond to give 2,4-dihydro derivative are 10-folds more active than the unsaturated compounds.
  • Substitution of a lipophillic group at 3 position increases the potency.
  • Substitution with the entities such as haloalkyl, aralkyl or thioether gives compounds with longer duration of action due to increased lipid solubility.
  • Alkyl substitution at the 2-N position can increase the action duration. [1]

 

Method of synthesis

i. Cyclization of 5-chloro-2,4-disulfamoylaniline by using urea to get 7-sulfamoyl-6-chloro-3-oxo-3,4-dihydro-2H-1,2,4-benzothiadiazine-1,1-dioxide.

ii. Above formed compound is reacted with methyliodide in presence of sodiumhydride, taking DMF as solvent to get an intermediate compound (I).

(I) reacts with sodium hydroxide to give the compound (II).

(II) reacts with chloroacetaldehyde to get methyclothiazide.

 

Medicinal Uses

Methyclothiazide is used for:

  • Management of hypertension
  • Management of edema related to CHF, chronic renal failure, glomerulonephritis, nephritic syndrome and hepatic cirrhosis.
  • To increase the effects of other antihypertensive drugs.

 

 Side Effects

Side effects of methyclothiazide are:

  • Nausea
  • Blurred vision
  • Vomiting
  • Dizziness
  • Fatigue
  • Diarrhea
  • Low blood sodium and potassium levels
  • Loss of appetite
  • Stomach cramps
  • Sexual problems
  • High blood sugar level
  • Low blood pressure
  • Muscle cramps
  • Fainting
  • Seizures

 

 

 

MCQs

Q.1 Mechanism of action of Methyclothiazide includes?

a) Prevention of active chloride reabsorption at the early distal tubule

b) Binding with thiazide sensitive Na-Cl transportor

c) None of these

d) Both a) and b)

Q.2 Therapeutic use of drug methyclothiazide is/are?

a) Management of diabetes

b) Treatment of Hypertension

c) Treatment of stable angina

d) All of the above

Q.3 Which of the following statement is correct related with the SAR of dihydropyridines calcium channel blockers?

a) Chlorothiazide is the simplest member of the series.

b) Hydrogen atom at the 2-N is most acidic due to presence of electron-withdrawing group.

c) Sulfonamide group at C-7 position provides additional acidity to the drug.

d) All of the above

Q.4 Number of chiral centers present in the structure of methyclothiazide?

a) 3

b) 2

c) 1

d) 0

Q.5 Correct sequence for the True/False for the physiochemical properties of the drug methyclothiazide can be?

I. Molecular weight = 246.3 gm/mol

II. Physical appearance = Colorless to yellowish liquid

III. Melting point = 173 oC

a) TFT

b) FFT

c) FFF

d) TTT

Q.6 Correct statements for the IUPAC nomenclatures of the drug are?

I. Methyclothiazide: 6-Chloro-3-(chloromethyl)-2-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide

II. Omeprazole: (RS)-6-(Difluoromethoxy)-2-[(3,4-dimethoxypyridin-2-yl)methylsulfinyl]-1H-benzo[d]imidazole

III. Methysergide: (RS)-1-[(4-chlorophenyl)- phenyl-methyl]-4- [(4-tert-butylphenyl) methyl] piperazine

IV. 5-FU: 1-cyano-2-methyl-3-[2-[(5-methyl-1H-imidazol-4-yl)methylsulfanyl]ethyl]guanidine

a) I, II, III, IV

b) III, IV

c) II, III, IV

d) I 

Q.7 Match the following drugs with their correct classifications-

i.  Methyclothiazide A. Diuretics
ii. Lansoprazole B. Antimetabolite
iii. Thioguanine C. Antihyperlipidemic
iv. Cholestipol D. Proton pump inhibitor

 a) i-A, ii-C, iii-D, iv-B

b) i-A, ii-D, iii-B, iv-C

c) i-D, ii-B, iii-A, iv-C

d) i-D, ii-A, iii-C, iv-B

 

 

 

 

For More Standard and Quality Question Bank you can Join Our Test Series Programme for GPAT, NIPER JEE, Pharmacist Recruitment Exam, Drug Inspector Recruitment Exams, PhD Entrance Exam for Pharmacy

Participate in Online FREE  GPAT  TEST: CLICK HERE

  Participate in Online FREE  Pharmacist  TEST: CLICK HERE 

Participate in Online FREE  Drug Inspector  TEST: CLICK HERE 

Participate in CSIR NET JRF Mock Test

Participate GATE Mock Test

 

 

ANSWERS

1-d

2-b

3-d

4-d

5-c

6-d

7-b

 

 

 

REFERENCES

 

[1] Lemke TL, Williams DA, editors. Foye’s principles of medicinal chemistry. Lippincott Williams & Wilkins; 2012 Jan 24.

2] Close, W.J. et al.: J. Am. Chem. Soc. (JACSAT) 82, 1132 (1960).

Developed By Connect Globes